Q4 EARNINGS: Abbott, Baxter, Bard and PerkinElmer see stock climb
This article was originally published in Clinica
Executive Summary
Abbott’s medical devices unit was once again its worst-performing, with Q4 sales falling 4% (flat at constant currency). Within devices, its diabetes care franchise did particularly badly, with revenues dipping 10%, while its drug-eluting stent and bioresorbable vascular scaffold unit, part of its vascular business, was also down 8%.